Sarepta 5051-101: A Phase 1 Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Treatment

Project: Research project

Project Details

StatusActive
Effective start/end date2/1/188/31/50

Funding

  • Sarepta Therapeutics, Inc.
  • Sarepta Therapeutics, Inc.